Search results
Results from the WOW.Com Content Network
Scheme of the complement system. The complement system, also known as complement cascade, is a part of the humoral, innate immune system and enhances (complements) the ability of antibodies and phagocytic cells to clear microbes and damaged cells from an organism, promote inflammation, and attack the pathogen's cell membrane. [1]
The alternative pathway is a type of cascade reaction of the complement system and is a component of the innate immune system, a natural defense against infections. The alternative pathway is one of three complement pathways that opsonize and kill pathogens. The pathway is triggered when the C3b protein directly binds a microbe. It can also be ...
Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the liver; [2] it is a type of viral hepatitis. [6] During the initial infection period, people often have mild or no symptoms. [1] Early symptoms can include fever, dark urine, abdominal pain, and yellow tinged skin. [1]
“Hepatitis C is a blood-borne virus,” says Dr. Dieterich. “It is transmitted through the blood, so IV drug use is a major driver of the virus, especially now due to the heroin epidemic.
For premium support please call: 800-290-4726 more ways to reach us
The classical pathway is distinct from the other complement pathways in its unique activation triggers and cascade sequence. Activation of the complement pathway through the classical, lectin or alternative complement pathway is followed by a cascade of reactions eventually leading to the membrane attack complex.
The complement system is a biochemical cascade of the immune system that helps, or "complements", the ability of antibodies to clear pathogens or mark them for destruction by other cells. The cascade is composed of many plasma proteins, synthesized in the liver, primarily by hepatocytes. The proteins work together to:
The FDA placed a partial clinical hold on a key next-generation hepatitis-C drug at the end of last week, and this week's second-quarter earnings were a mixed bag, sending shares FDA Slams Brakes ...